The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.

“For patients with cardiovascular disease, abortion access is a critical part of their comprehensive cardiovascular and reproductive care,” according to the three authors of a new commentary piece in JAMA Cardiology.

The new guidance document was designed to provide helpful information on a topic "surrounded by controversy." 

The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.

Kirk Garratt, MD, medical director of the Center for Heart and Vascular Health, ChristianaCare, and a past president of SCAI, explains what this shortage means for interventional cardiologists.

Patients with higher levels of extravalvular cardiac damage prior to TAVR or SAVR face a higher risk of dying within two years, according to new findings presented at EuroPCR 2022 in Paris.

Vivasure Medical will use the funds to advance clinical development and attempt to secure regulatory approval of its vessel closure devices.

Two separate sessions presented at SCAI 2022 focused on long-term outcomes associated with Shockwave Medical's IVL technology.

Drug shortages have been impacted by COVID-19, with 95% of doctors believing the pandemic exposed weaknesses in the medicine supply chain.